216 related articles for article (PubMed ID: 25970013)
1. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
2. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
5. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
6. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
7. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
[No Abstract] [Full Text] [Related]
8. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
[No Abstract] [Full Text] [Related]
11. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig
Yoshida T; Leen Liew E; Ota M; Nakayama H; Yanagihara Y; Nakamura Y; Seriu T; Kamishohara M
Nihon Yakurigaku Zasshi; 2017; 150(1):54-61. PubMed ID: 28690276
[No Abstract] [Full Text] [Related]
14. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Boo YL; Liam CCK; Toh SG; Lim SM
Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
[No Abstract] [Full Text] [Related]
15. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
17. In brief: ponatinib (Inclusig) returns.
Med Lett Drugs Ther; 2014 Jan; 56(1434):8. PubMed ID: 24457561
[No Abstract] [Full Text] [Related]
18. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation.
Goodrich AD
Expert Rev Hematol; 2014 Oct; 7(5):513-5. PubMed ID: 25199408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]